BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MeiraGTx Limited readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies MeiraGTx Limited's drugs run\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05894343-8717@assetmemo.bio
DTSTAMP:20261121T010150Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:AAV-GAD gene therapy: Phase 1/2 readout est. (NCT05894343)
DESCRIPTION:AAV-GAD gene therapy\, phase 1/2\, Parkinson's Disease.\nStudy:
  Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in
  Parkinson's Disease\nEstimated primary completion: October 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/aav-gad-gene-therapy#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05894343
URL:https://assetmemo.bio/drug/aav-gad-gene-therapy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
